华东医药：全资子公司收到药品注册受理通知书

Core Viewpoint - Huadong Medicine announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., received the Acceptance Notification from the National Medical Products Administration (NMPA) for the marketing authorization application of Edaravone Tablets (R&D code: TTYP01) for the treatment of acute ischemic stroke [1] Group 1 - The application for Edaravone Tablets has been officially accepted by the NMPA [1] - The acceptance of the application marks a significant step towards potential commercialization of the drug [1] - The drug is specifically aimed at treating acute ischemic stroke, indicating a focus on critical healthcare needs [1]